|Bid||5.56 x 3100|
|Ask||5.98 x 800|
|Day's Range||5.55 - 5.80|
|52 Week Range||2.50 - 9.49|
|Beta (5Y Monthly)||2.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 02, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.29|
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CAMBRIDGE, Mass., March 09, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.
Q4 2022 Seres Therapeutics Inc Earnings Call